These results are corroborated in patients who have been previously treated with platinum compounds or PARP inhibitors [8].PARP inhibition heightens tumor cell sensitivity to DNA-damaging treatments like platinum agents, temozolomide, and radiation. Here, PARP1 is linked to neoplasm.